[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Oncology Clinical Evidence Synopsis
August 2016

Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation

Author Affiliations
  • 1NHS Blood and Transplant, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford, Oxford, England
JAMA Oncol. 2016;2(8):1091-1092. doi:10.1001/jamaoncol.2016.2466

Clinical Question  What is the optimal platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant neoplasms?

Bottom Line  Maintaining a higher platelet count threshold (≤20 × 109/L or ≤30 × 109/L) was not associated with less bleeding than the current standard (≤10 × 109/L), but required more platelet transfusions (low-quality evidence).